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The interaction of inhibitory killer cell Ig-like receptors (KIRs) with human leukocyte 
antigen (HLA) class I molecules has been characterized in detail. By contrast, activating 
members of the KIR family, although closely related to inhibitory KIRs, appear to interact 
weakly, if at all, with HLA class I. KIR2DS1 is the best studied activating KIR and it inter-
acts with C2 group HLA-C (C2-HLA-C) in some assays, but not as strongly as KIR2DL1. 
We used a mouse 2B4 cell reporter system, which carries NFAT-green fluorescent 
protein with KIR2DS1 and a modified DAP12 adaptor protein. KIR2DS1 reporter cells 
were not activated upon coculture with 721.221 cells transfected with different HLA-C 
molecules, or with interferon-γ stimulated primary dermal fibroblasts. However, KIR2DS1 
reporter cells and KIR2DS1+ primary natural killer (NK) cells were activated by C2-HLA-C 
homozygous human fetal foreskin fibroblasts (HFFFs) but only after infection with specific 
clones of a clinical strain of human cytomegalovirus (HCMV). Active viral gene expression 
was required for activation of both cell types. Primary NKG2A−KIR2DS1+ NK cell subsets 
degranulated after coculture with HCMV-infected HFFFs. The W6/32 antibody to HLA 
class I blocked the KIR2DS1 reporter cell interaction with its ligand on HCMV-infected 
HFFFs but did not block interaction with KIR2DL1. This implies a differential recognition 
of HLA-C by KIR2DL1 and KIR2DS1. The data suggest that modulation of HLA-C by 
HCMV is required for a potent KIR2DS1-mediated NK cell activation.
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inTrODUcTiOn
Since the discovery of natural killer (NK) cells more than 40 years ago (1–3), the interaction of inhibi-
tory NK cell receptors with human leukocyte antigen (HLA) class I molecules has been characterized 
in detail. This led to new insights into NK cell differentiation, education, and function. However, 
ligands of most activating receptors, including activating killer cell Ig-like receptors (KIRs), are yet 
to be discovered.
2van der Ploeg et al. HCMV Affects KIR2DS1 Recognition
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 298
KIR genes are members of the immunoglobulin (Ig) super-
family, encoded in the leukocyte receptor complex (LRC) on 
chromosome 19q14.3 (4). KIR molecules express either two or 
three extracellular Ig-like domains (2D or 3D) and consist of 
either a long (designated “L”) or short (designated “S”) cytoplas-
mic domain. KIRs with long cytoplasmic domains are inhibitory 
(iKIRs) and contain ITIMs. Activating KIRs (aKIRs) have a short 
cytoplasmic tail and transmit activating signals through the 
interaction with DAP12, which contains an ITAM (4).
Most iKIRs recognize certain allotypes of HLA class I. In gen-
eral, allelic products of KIR2DL1 bind to the C2 group of HLA-C 
molecules (C2-HLA-C) characterized by Asn77 and Lys80 (5), 
while KIR2DL2 and -2DL3, which are alleles at the same locus, 
recognize the C1 group (C1-HLA-C, Ser77, and Asn80) (6–8). 
These structural motifs were originally thought to be essential for 
the engagement of KIRs only on HLA-C. However, KIR2DL2 can 
also bind HLA-B46:01 and -B73:01 alleles, which have C1-related 
motifs at residues 77–83 (9). Furthermore, KIR2DL2 and -L3 
receptors can bind many HLA-C alleles irrespective of -C1 or 
-C2 group (10, 11).
The extracellular parts of iKIRs and aKIRs are highly 
homologous and share conserved amino acid sequences, as 
“paired” receptors (11, 12). The balance between inhibitory and 
activating signaling through these paired receptors is tightly 
regulated by NK  cells. Dysregulation of this balance might 
lead to autoimmunity or infectious diseases (13, 14). How the 
signaling is controlled by NK cells, however, is not completely 
understood, mainly due to uncertainty over the ligands and 
functions of aKIRs. The aKIR members seem to have evolved 
more rapidly than iKIRs, possibly through selection pressure 
imposed by pathogens (15, 16). If this hypothesis is true, it 
suggests that aKIR binding may be influenced by pathogen-
derived proteins. Notably, KIR2DS1 and -2DS2 counterparts in 
chimpanzees, respectively, bind C2- and C1-HLA-C with high 
avidity compared to their inhibitory paired receptors (17). This 
indicates that the loss of binding by KIR2DS2, or highly reduced 
binding of KIR2DS1, to HLA-C is a product of human-specific 
evolution.
Most interactions of aKIRs and HLA class I molecules are 
very weak or undetectable (17–23). The best studied aKIR is 
KIR2DS1 and many studies have found that it binds C2-HLA-C 
(10, 11, 17, 24–35). However, this binding is much weaker com-
pared to KIR2DL1 (10, 25, 27). Using surface plasmon reso-
nance (SPR) analysis, Stewart and colleagues demonstrated that 
KIR2DS1 tetramer-binding avidity to the soluble HLA-Cw4/
beta-2 microglobulin (β2M)/peptide complex is approximately 
four times lower than KIR2DL1: dissociation constants (Kd) of 
7.2 and 30 μM, respectively. In addition, amino acid substitu-
tion of the peptide at amino acid 7 or 8 drastically reduced 
KIR2DS1 tetramer binding to the HLA-Cw4 complex, indicat-
ing that the binding is peptide dependent (27). Both Moesta 
et al. and Hilton et al. demonstrated that KIR2DS1-Fc binds a 
range of C2-HLA-C allotypes linked to microbeads with differ-
ent avidity (11, 17). Biassoni and colleagues demonstrated that 
the amino acid at position 70, a threonine in KIR2DL1 and a 
lysine in KIR2DS1, is the key residue that differentiates binding 
between KIR2DL1 and -2DS1. Substituting the threonine to 
a lysine in KIR2DL1-Fc prevented binding to 721.221 trans-
fected with HLA-Cw4 (221-Cw4). When lysine was substituted 
for a threonine in KIR2DS1-Fc, the binding to 221-Cw4 was 
restored (25).
The rationale for KIR2DL1 and KIR2DS1 both binding 
C2-HLA-C would be understandable if the activating receptor 
was sensitive to structural changes in the HLA molecule, or 
bound an alternative molecule, induced by viral infection (18, 
27, 36–42). For example, in mice, the cytomegalovirus (CMV)-
encoded MHC class I homolog m157 is directly recognized by 
the activating Ly49H receptor (43). The mouse Ly49 receptor 
family serves a similar role to KIRs in humans, although KIRs 
and Ly49 receptors are from different molecular families. KIRs 
play an important role in human cytomegalovirus (HCMV) 
infections (44–47). For instance, a recent study demonstrated 
that KIR2DS1+ decidual NK (dNK) cells degranulated after 
engaging with HCMV-infected decidual stromal cells (DSC), 
suggesting an increased ability of KIR2DS1-expressing dNK cells 
to respond to placental HCMV infection (47). Della Chiesa et al. 
have reported that HCMV can drive NK cell maturation in the 
absence of NKG2C in patients with hematological malignan-
cies. These patients received umbilical cord blood transplanta-
tion from NKG2C−/− donors and when HCMV reactivation 
occurred, an expansion of NKG2A− NK cells expressing aKIRs 
was measured, particularly KIR2DS1 and KIR3DS1 (45). This 
finding is consistent with KIR2DS1 recognizing a ligand on 
HCMV-infected cells.
To probe the potential influence of HCMV on KIR2DS1 
recognition, we designed a mouse 2B4 T cell hybridoma carrying 
an NFAT-green fluorescent protein (GFP) reporter. Our results 
suggest that modulation of HLA-C by HCMV is required for a 
potent KIR2DS1-mediated NK cell activation.
MaTerials anD MeThODs
cell lines and cell culture
Reporter cells, 721.221 cells, K562 cells, and primary NK cells were 
cultured in RPMI-1640 (Sigma-Aldrich, Steinheim, Germany) 
supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin 
(Gibco, Paisley, UK), and 10% heat-inactivated Fetal Bovine 
Serum (Gibco). Human fetal foreskin fibroblasts (HFFFs, Culture 
Collections—ECACC, UK) and primary dermal fibroblasts (DFs) 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Sigma-Aldrich) supplemented with 100 U/ml penicillin, 100 μg/
ml streptomycin (Gibco), and 10% heat-inactivated fetal bovine 
serum. Adherent cells were harvested by washing the cells once 
with phosphate buffered saline (PBS, Sigma-Aldrich). Then the 
cells were either detached from the plastic using 0.05% Trypsin/
EDTA (Gibco) or Accutase™ (Biolegend, San Diego, CA, USA) 
for 5  min at 37°C. All cellular experiments were performed at 
37°C in 5% CO2.
721.221 cells transfected with -A23:01, -B58:01 (Bw4), -B35:01 
(Bw6), -C01:02 (C1), -C02:02 (C2), -C03:02 (C1), -C04:01 (C2), 
-C06:02 (C2), -C07:01 (C1), and -HLA-G were generated in 
house. 721.221-HLA-A11:02 was provided by Parham (22) 
(Stanford University, Palo Alto, CA, USA).
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establishment of the reporter cells
The 2B4 T cell hybridoma containing an NFAT-GFP reporter gene 
(2B4 reporter cells) was kindly provided by Lewis Lanier (43) 
(University of California San Francisco, USA). KIR2DL1*003, 
-2DL2*001, -2DS1*002, and -2DS1(K70T) reporter cells were gener-
ated as follows. First, pMX-neo constructs containing cDNA from 
a chimeric adaptor protein recombinant was used to transduce the 
2B4 reporter cells. The chimeric adaptor consists of DAP12 and 
a cytoplasmic tail of DAP10 with spacer sequences in between. 
Then cDNA of the indicated KIRs was subcloned into a pMX-
puro construct. For constructing 2DL1–2DS1TM (KIR2DL1 
reporter) and 2DL2–2DS1TM (KIR2DL2 reporter) chimeric mol-
ecules, 5′-CCTGCACGTTCTGATTGGGACCTCAGT-3′ and 
5′-CCCAATCAGAACGTGCAGGTGTCGGGGGTT-3′ primers 
were used. 5′-AGTCGCATGACGCAAGACCTGGCAGGG-3′ 
and 5′-GGTCTTGCGTCATGCGACTGATGGAG-3′ prim-
ers were used for constructing the KIR2DS1(K70T) reporter cell. 
Retroviruses were packaged in Phoenix-eco cells (generously 
provided by Lewis Lanier) using the non-modified polyethyl-
eneimine (PEI, Sigma-Aldrich) reagent as described by Ehrhardt 
et al. (48). After 48 h, supernatant-containing retroviral particles 
was used to transduce the 2B4 reporter cells by adding Polybrene 
(8  ng/ml, Sigma-Aldrich) and by spin-infecting the cells at 
2,500 rpm (AccuSpin 3R centrifuge, Fisher Scientific, Waltham, 
MA, USA) for 2  h. Cells expressing the KIRs were purified by 
surface staining using the PAN2D antibody (clone NKVFS1, Bio-
Rad, Hercules, CA, USA), followed by single-cell sorting using 
the FACS sorter (BD Bioscience, Oxford, UK). The transduction 
success and the function of the reporter cells were analyzed 
by immunofluorescent staining and antibody crosslinking, as 
described below. The LILRB1 reporter cell was provided by Des 
Jones (Department of Pathology, University of Cambridge) and 
was constructed as described in Ref. (49).
Primary cells
Primary NK  cells and DFs were obtained from healthy indi-
viduals. Ethical approval for the use of these tissues was given 
by Addenbrookes National Health Service Hospital Trust insti-
tutional review board (Cambridge Research Ethics Committee) 
and informed written consent was obtained from all volunteers 
in accordance with the Declaration of Helsinki (LREC 97/092). 
The primary fibroblasts were fully HLA typed. HFFFs express 
HLA-A11:01, -A24:02, -B35:02 (Bw6), -B40:02 (Bw6), -C02:02 
(C2), and -C04:01 (C2). Donor CMV307 expresses HLA-A01:01, 
-A26:01, -B08:01 (Bw6), -B27:05 (Bw4), -C07:01 (C1), and 
-C01:02 (C1). Donor CMV0005 expresses HLA-A02, -A03, -B07 
(Bw6), -B13 (Bw4), -C07 (C1), and -C06 (C2). Primary NK cell 
donors both express KIR2DL1, -2DS1, 2DL3, NKG2A, and were 
C1/C1-HLA-C. In addition, donor 016 expresses NKG2C and 
donor 111 expresses KIR3DL1.
For functional NK cell studies, peripheral blood mononuclear 
cells (PBMCs) were extracted from 30 to 40 ml blood of donor 
016 and 111 on a Ficoll-Hypaque density gradient (Lympoprep, 
Axis-Shield, Dundee, Scotland). The PBMCs were removed from 
the interface of the plasma and Lymphoprep layers and washed 
three times with PBS before further use. NK cells were separated 
from the PBMCs by negative selection using the EasySep™ 
Human NK  cell Enrichment Kit from Stemcell Technologies 
(Vancouver, BC, Canada).
Dermal biopsies were taken from healthy individuals by 
Andrew Carmichael (Department of Medicine, University 
of Cambridge). They were sectioned with a scalpel and were 
grown beneath cover slips in a six-well culture plate containing 
Eagle’s Minimum Essential Media (EMEM, GE Healthcare, Little 
Chalfont, UK) supplemented with 100 U/ml penicillin, 100 μg/ml 
streptomycin (Gibco), and 10% heat-inactivated fetal calf serum 
(Life Technologies, Carlsbad, CA, USA). The cells were grown 
until sufficient cell number was reached and were stored in liquid 
nitrogen at low passage numbers.
coculture experiments
Human fetal foreskin fibroblasts (10 ×  103 cells/well) and DFs 
(10 × 103 cells/well) were seeded in 96-well flat-bottom culture 
plates with or without interferon (IFN)-γ (500 U/ml, PeproTech, 
Rocky Hill, CT, USA) for 72 h or infected with HCMV as described 
below. After appropriate stimulation/infection time was reached, 
reporter cells were added to the adherent cells at a concentration 
of 2 × 104 cells per well, and reporter cells were added directly. 
Cocultures using K562 cells and 721.221 cells were performed 
at an E:T ratio of 1:1 and 1:3, respectively. After an overnight 
coculture, the reporter cells were harvested, and GFP expression 
was analyzed by flow cytometry.
antibody cross-linking
For antibody crosslinking experiments, anti-mouse IgG-coated 
microplates (R&D systems, Minneapolis, MN, USA) were used. 
The plates were incubated for 30  min with 0.2–1  μg per well 
of PAN2D (clone NKVFS1) or anti-HA (clone HA-7, Sigma-
Aldrich) antibodies in PBS at room temperature. After two PBS 
washes, the reporter cells were added.
antibody-Blocking assays
Unconjugated W6/32 (LEAF™ purified BioLegend), 6A4 (gift 
from Daniela Pende, Azienda Ospedaliera Universitaria San 
Martino di Genova), B1.23.2 (eBiosciences, San Diego, CA, USA), 
IgG2a (LEAF™ purified BioLegend), IgG2b (LEAF™ purified 
BioLegend), and IgG1 (LEAF™ purified BioLegend) isotype 
antibodies were added to pre-treated HFFFs. After an incubation 
of 10–15 min at room temperature and saturating concentration 
of 1–4 μg per well, the reporter cells were added.
Flow cytometry
Immunofluorescence Cell-Surface Staining
The cells were harvested and rested at 37°C in 5% CO2 for at least 
30 min for the recovery of HLA class I molecules on the cell sur-
face. Cells expressing Fc receptors or HCMV-encoded Fc recep-
tors were first blocked with 40% human serum (Sigma-Aldrich) 
in PBS for at least 5 min before staining. Fractions of 721.221 cells 
were collected and directly incubated with the appropriate anti-
body. Cell-surface expression of different receptors was analyzed 
by immunofluorescent staining using unconjugated monoclonal 
primary antibodies listed in Table 1, unconjugated anti-HLA-E 
(3D12, IgG1, BioLegend), biotinylated anti-HLA-A11 (Abcam, 
TaBle 1 | list of antibodies and their target epitopes where known.
antibody isotype/supplier recognition specific hla molecules reference
W6/32 IgG2a/BioLegend, 
Hybridoma
β2M bound, fully assembled human leukocyte antigen (HLA) class I molecules. The 
epitope is not known. It includes residues on β2M, α2, and α3 domains
HLA-A, -B, -C and HLA-E, -G (50, 51)
B1.23.2 IgG2b/eBiosciences β2M bound, fully assembled HLA-B and -C molecules. Precise epitope unknown HLA-B and HLA-C (52)
6A4 IgG1/Hybridoma β2M bound, fully assembled HLA-B and -C molecules. Precise epitope unknown HLA-B and HLA-C (53)
HC10 IgG2a/Hybridoma Free heavy chain of HLA class I. Residues 57–62, specifically residue 60 in the α1 
domain in HLA-C. The epitope is blocked by peptide binding
HLA-B and HLA-C and some 
HLA-A (A10, A28, A29, A30, A31, 
A32, A33)
(54, 55)
DT9 IgG2b/Hybridoma Fully assembled HLA-C and HLA-E bound to β2M. Precise epitope unknown HLA-C and HLA-E (56)
L31 IgG1/MediaParma Free heavy chain of HLA-C. Residues 66–68, with F or Y at position 67 Most HLA-C and a few HLA-B 
(B08, B07, B35, B51, B54, B56)
(57)
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IgM, Cambridge, UK), APC-conjugated anti-HLA-Bw6 (IgG1, 
Miltenyi Biotec, Bergisch Gladbach, Germany), and the appro-
priate isotype control antibodies. The primary antibodies were 
added at a concentration of 0.5–1 μg per well in 5% FCS in PBS 
or 40% human serum in PBS and incubated on ice for 45 min. 
Following washing, the cells were incubated with secondary anti-
bodies (0.4–1 μg per well), AlexaFluor® 647 (AF647)-conjugated 
Streptavidin (Life Technologies) and polyclonal anti-mouse IgG 
conjugated to FITC (BD Pharmingen, San Diego, CA, USA), 
AF647 (Life Technologies), or R-PE (Thermo Scientific), in 5% 
FCS with PBS or in 40% human serum with PBS for 30 min on ice. 
For double staining experiments, the W6/32 antibody or IgG2a 
isotype control conjugated to AF647 or FITC (BioLegend) was 
added to the cells for 30 min on ice. The cells were fixed with 1% 
formaldehyde in PBS before flow cytometry analysis.
Functional Assay with Primary NK Cells Including 
Subsequent Multicolor Immunofluorescence Staining
Natural killer cells were stimulated with medium alone or with 
IL-12 (10  ng/ml, R&D systems) and IL-15 (50  ng/ml, R&D 
systems) for 12 h. The following day, target cells were added at 
an E:T ratio of 1:1 or 10:1 (58). Cytokine-stimulated NK cells in 
medium alone, or cocultured with K562 cells (a gold standard 
NK cell target cell line, devoid of MHC class I) served as a positive 
control for function when HCMV-infected HFFFs were investi-
gated for their capacity to trigger primary NK cells. After 1 h of 
coculture, GolgiPlug (Brefaldin A, BD Bioscience) and GolgiStop 
(Monensin, BD Bioscience) were added to the wells according to 
manufacturer’s instructions, and incubated for an additional 4 h. 
Non-adherent cells were subsequently transferred to V-bottom 
well plates where multicolor immunofluorescence staining was 
performed (32). The following conjugated monoclonal antibodies 
were used: anti-KIR2DL3 FITC (REA147, Miltenyi), anti-NKG2A 
APC (Z199, Beckman Coulter, Brea, CA, USA), anti-CD107a 
APC-H7 (H4A3, BD Bioscience), anti-KIR3DL1 Brilliant Violet 
421 (DX9, BioLegend), biotinylated anti-KIR2DL1 (143211, R&D 
Systems), anti-CD56 ECD (N901, Beckman Coulter), anti-CD3 
PE-Cy5 (UCHT-1, BioLegend), and anti-KIR2DL1/S1 PE-Cy7 
(EB6, Beckman Coulter). Briefly, the cells were stained with 
the primary antibody cocktail for 20  min. The anti-KIR2DL1/
S1 antibody was added directly to the wells (dilution 1:20) for 
10 min incubation. Following washing, the secondary antibody 
cocktail containing Live/Dead Aqua (Invitrogen, Carlsbad, CA, 
USA) and Qdot-605-conjugated Streptavidin (Invitrogen) was 
incubated for 20 min. Cells were next washed and fixed.
Data acquisition for the cellular and immunofluorescence 
cell-surface staining experiments was performed on FACScan 
(Department of Pathology), FACSCalibur or Accuri C6 flow 
cytometer (NIHR Cambridge BRC Cell Phenotyping Hub, BD 
Bioscience) depending on the experiment. The data acquisition 
of the multicolor primary NK  cell staining experiments was 
performed on a BD LSR Fortessa flow cytometer, equipped with 
4 lasers and 13 PMTs (Cambridge Stem Cell Institute). Flow 
cytometry data were analyzed using FlowJo software (TreeStar, 
OR, USA).
Viruses
Human cytomegalovirus strains TB40/E [isolated from a throat 
wash of a bone marrow transplant recipient (59)], AD169 (ATCC 
VR-538) and Merlin (a gift from Richard Stanton, University of 
Cardiff, UK) were grown, concentrated, and titrated as described 
previously (60). Confluent plates of HFFFs or DFs were infected 
with concentrated virus (TB40/E, AD169, Merlin) at a multiplicity 
of infection (MOI) as indicated in the experiment or with diluted 
(1:10) supernatant-containing virus (TB40/E-derived clones). 
The virus preparations were diluted in complete DMEM to 
obtain the required MOI. After 1 h of infection at room tempera-
ture, the cells were washed with PBS, and fresh complete DMEM 
was added. A coculture experiment was performed, or the cells 
were harvested for cell-surface staining, or western blotting, 24, 
48, and/or 72 h p.i. as indicated in the experiment. Time points 
were chosen to reflect the temporal cascade of expression of 
HCMV viral proteins (immediate early, early, and late genes). Late 
genes, which are structural viral components, are last expressed 
at ~72 h post infection (p.i.) (61). UV inactivation of the virus 
was obtained by exposing the virus 30 min to UV light of a 30 W 
germicidal lamp.
Plaque Purification assay
Human fetal foreskin fibroblasts were infected with serially 
diluted HCMV strain TB40/E. After 1 h of infection at room tem-
perature, the virus-containing medium was replaced with 5 ml 
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per well of 2% agarose mixed 1:1 with two times concentrated 
DMEM medium (Millipore, Bedford, MA, USA) containing 20% 
FCS, 200 U/ml penicillin, 200 μg/ml streptomycin, 8 g/L sodium 
bicarbonate (GE Healthcare), and 1  mM of sodium pyruvate 
(Sigma-Aldrich). After 3 weeks, plaques (areas of dead cells) were 
visible by eye. Well-separated plaques, representing different viral 
clones of the TB40/E wild-type strain, were picked using a glass 
Pasteur pipette by removing the agar and plaque as a plug. The 
agarose plug containing viral clones were disrupted and added 
to freshly plated HFFFs in 96-well flat-bottom culture plates to 
expand the viral clones. Selected clones were expanded up to a 
75 cm2 culture flask. After 100% infection was reached, as deter-
mined visually by microscopy, the supernatant-containing virus 
was harvested and stored at −80°C. Fresh complete DMEM was 
added to the flasks and further harvests were carried out every 
72 h until approximately 90% cell lysis was visually determined. 
All the harvested supernatant was pooled, spun at 2,000 rpm to 
remove cell debris, aliquoted, and stored at −80°C.
Western Blot
Cells were washed with PBS and lysed in lysis buffer [1% 
Triton X-100, 20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM 
EDTA, 5  mM MgCl2, protease inhibitors (Roche, Mannheim, 
Germany), and 1  mM Phenylmethanesulfonyl fluoride (PMSF, 
Sigma-Aldrich) and 1.25  mg/ml N-ethylmaleimidine (Sigma-
Aldrich)] for 20 min at 4°C. Debris and nuclei were removed by 
centrifugation at 13,000  rpm (centrifuge HAWK 15/05, MSE), 
and a bicinchoninic acid (BCA) assay (Thermo Scientific) was 
used to determine protein concentrations.
Supernatants of TB40/E-derived clones were pelleted by 
centrifuging at 15,000 rpm for 2 h at 4°C using an Avanti J-25 
Ultracentrifuge (Beckman Coulter). The virus pellets were gently 
washed with PBS, and 200 μl of lysis buffer was added to lyse the 
particles. Lysates from positive and negative virus particles were 
paired based on approximately the same infectivity titer. Virus 
titers were calculated by TCID50.
Total cell or virus particle lysates were loaded onto a 10–13% 
SDS-PAGE gel, and proteins were transferred onto Immobilon-P 
PVDF membranes (Millipore). The membranes were blocked 1 h 
in PBS, 5% dried milk, and 0.05% Tween 20 at room tempera-
ture. The membranes were incubated overnight at 4°C or 3 h at 
room temperature with primary antibodies [anti-pp28 (Abcam), 
L31, HC10, anti-I.E.1 (Merck Millipore, Billerica, MA, USA), 
anti-Calnexin (Enzo Life Sciences, Farmingdale, NY, USA), and 
anti-Flag (M2, Sigma-Aldrich)] at concentration of 0.1–0.2 μg. 
The membranes were washed thoroughly, and polyclonal HRP-
conjugated goat anti-mouse IgG or goat anti-rabbit IgG (Dako, 
1:4,000 dilution) secondary antibody was added for 30  min at 
room temperature. Chemiluminescence was performed accord-
ing to the manufacturer’s instructions using ECL Prime (GE 
Healthcare) or home-made ECL (62).
establishment crisPr-cas9 Knockout 
(KO) for β2M in hFFFs
Streptococcus pyogenes CAS9 and short-guide RNA (sgRNA) were 
expressed in separate lentivirus constructs: pHRSIN containing 
the SFFV promoter, FLAG tag, nuclear localization signals (NLS), 
CAS9 and pGK Hygro (kind gift from Lehner’s group, CIMR, 
University of Cambridge), and pKLV-containing U6 promoter, 
sgRNA (modified BbsI), pGK Puro, 2A, and BFP tag [Addgene 
plasmid #50946; created by Kosuke Yusa, Wellcome Trust Sanger 
Institute, Cambridge, UK (63)]. The pKLV construct containing 
sgRNA-targeting β2M was a gift from Dick van den Boomen 
(CIMR, University of Cambridge), using the sgRNA sequence 
5′-GGCCGAGATGTCTCGCTCCG-3′.
The pHRSIN and pKLV lentivirus constructs (6  μg) were 
packaged together with pMDG and pCMV9.81 packaging 
vectors (4 μg) in HEK 293T cells in 75 cm2 culture flasks using 
Opti-MEM™ and GlutaMax™ media (Gibco), and TransIT® 
Transfection reagent (Mirus, Madison, WI, USA). After 48  h, 
supernatant-containing lentiviral particles were used to transduce 
HFFFs in 75 cm2 culture flasks by adding Polybrene (8 ng/ml). 
The transduced cells were selected with 200 μg/ml hygromycin 
and/or 2 μg/ml puromycin and grown until a confluent 75 cm2 
culture flask was reached. Cells negative for total HLA class I were 
purified by surface staining using W6/32 antibody, respectively, 
followed by single-cell sorting using the FACS sorter. The CAS9 
is FLAG-tagged and a HRP-conjugated anti-M2 FLAG antibody 
was used to detect it by western blot.
statistical analysis
Non-parametric one-way analysis of variance (ANOVA) using 
the Kruskal–Wallis test and Dunn’s multiple comparisons test 
was used to determine the statistical significance. In these tests, 
a p value of less than 0.05 was considered significant (*p < 0.05, 
**p < 0.01). The tests were done with GraphPad Prism version 
6.00 (GraphPad software).
resUlTs
The Function and specific recognition of 
Kir2Ds1 by reporter cells
Since KIR2DS1 binds C2-HLA-C only weakly, we aimed to 
investigate what might influence stronger binding. To accomplish 
this, we used a specifically designed mouse 2B4 T cell hybridoma 
carrying an NFAT-GFP reporter system, similar to that described 
by Arase et  al. (43). KIR2DS1 was transduced into these 2B4 
reporter cells, together with a modified adaptor protein. Once 
KIR2DS1 binds its cognate ligand, a signaling cascade is triggered 
through the adaptor protein, which then transcribes NFAT, result-
ing in GFP expression. KIR2DL1, -2DL2, and LILRB1 reporter 
cells were also generated. We confirmed that the reporter cells 
were constructed successfully by staining the surface expression 
of the different receptors with the relevant antibodies and by 
engaging the reporter cells with relevant plate-bound antibodies 
(Figure 1A).
There are seven amino acid differences between KIR2DL1 
and -2DS1 alleles, including the threonine to lysine in KIR2DL1 
and -2DS1 at position 70, respectively (Figure 1B). We wanted 
to investigate whether substituting the lysine to a threonine at 
position 70 in KIR2DS1 would result in the activation of the 
reporter cells as a result of the interaction with C2-HLA-C, 
FigUre 1 | continued 
2B4 reporter system for activating killer cell ig-like receptor (Kir). 
(a) Cell-surface expression on the indicated reporter cells was measured by 
flow cytometry after staining the cells with PAN2D (clone NKVFS1, 
recognizes all KIRs) or anti-HA antibody (black line, left panel). Parental 2B4 
cells containing only the adaptor protein were used as a negative control. To 
test the function of these reporter cells, plate-bound PAN2D (clone NKVFS1) 
or anti-HA (LILRB1 reporter only) antibody crosslinking (black line) was used 
to engage KIR or LILRB1 molecules on the reporter cells during an overnight 
incubation (right panel). IgG1 antibody was used as isotype control (dotted 
line). (B) Table depicting amino acid positions of polymorphic sites in the 
extracellular domain of KIR2DL1 and -2DS1 alleles. Large letters indicate 
amino acids present in the majority of alleles, and small letters indicate 
amino acids that are present in few alleles. At position 70, a unique amino 
acid in KIR2DL1 and -2DS1, threonine (T) and lysine (K), respectively, was 
found. Allele sequences were aligned using the alignment tool in the IPD-KIR 
database. (c) KIR2DS1(K70T) was transfected into the 2B4 reporter system 
and an overnight coculture was performed using KIR2DL1, -2DS1, or 
-2DS1(K70T) reporter cells together with 721.221 cells expressing human 
leukocyte antigen (HLA)-Cw3 (C1) or HLA-Cw6 (C2). The next day green 
fluorescent protein (GFP) expression was measured by flow cytometry. The 
E:T ratio of the coculture was 1:3.
FigUre 1 | continued
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Kir2Ds1 reporter cells Do not recognize 
conventional hla class i
To verify whether KIR2DS1 reporter cells are activated by 
conventional HLA class I molecules, cocultures were performed 
using the KIR2DS1 reporter cells along with appropriate controls. 
The cocultures were done using a range of 221 cells transduced 
with different HLA molecules: HLA-A11:02, -A23:01, -Bw6 
(B35:01), -Bw4 (B58:01), -G, -C01:02 (C1), -C02:02 (C2), -C03:02 
(C1), -C04:01 (C2), -C06:02 (C2), and -C07:01 (C1). HLA 
expression levels on these 221 cells were confirmed by staining 
with W6/32 antibody (Figure 2A). KIR2DS1 reporter cells were 
not activated in cocultures with different 221-HLA-C or other 
221-HLA class I cells. However, the positive controls KIR2DL1, 
-L2, and LILRB1 were activated after engaging their documented 
ligands (Figures 2B,C). As expected, KIR2DL1, -L2, and LILRB1 
reporter cells were differentially activated, depending on the 
HLA-C allele they engaged. For instance, the KIR2DL2 reporter 
cell was weakly activated after binding HLA-C01:02 (<5% GFP-
positive cells) compared to HLA-C07:01 (>20% GFP cells), as 
depicted in Figure 2C, lower panel. This is in line with binding 
studies using Fc proteins and HLA-coated beads (11, 64).
In our hands, the KIR2DS1 reporter cells did not recognize 
endogenously expressed HLA class I molecules on 221 cells. To 
investigate this further, they were cocultured with primary cells: 
HFFFs, CMV307, and CMV0005 DFs, which were stimulated 
with or without IFN-γ for 72  h. Before the coculture experi-
ments, HLA class I surface expression levels of untreated and 
IFN-γ stimulated cells were measured. The primary fibroblasts 
all expressed high levels of folded HLA class I and HLA-C/-E 
molecules, revealed by W6/32 and DT9 antibody staining, 
respectively. These HLA class I levels were further increased 
after 72 h of IFN-γ stimulation (Figure 3A). KIR2DS1 reporter 
cells remained GFP-negative when cocultured with the different 
untreated or IFN-γ stimulated primary fibroblasts (Figure 3B). 
By contrast, LILRB1 reporter cells were activated in all coculture 
experiments with untreated cells and were further activated in 
as demonstrated previously by Biassoni and colleagues using 
Fc proteins (25). We made the KIR2DS1(K70T) reporter cell and 
cocultured these cells with 721.221 transfected with HLA-
C03:02 (C1) or -C06:02 (C2) (221-Cw3 or 221-Cw6). Indeed, 
both KIR2DL1 and KIR2DS1(K70T) reporter cells were activated 
after coculture with 221-Cw6 (15 and 11% GFP-positive cells, 
respectively) and not with 221-Cw3 (Figure 1C). This confirms 
the observations made by Biassoni et al. in our cellular reporter 
system and shows that the reporter cells are functional, specific, 
and sensitive.
FigUre 2 | Kir2Ds1 reporter cells are not activated by conventional human leukocyte antigen (hla) class i molecules. (a) The 721.221-HLA 
transfectants were stained with W6/32 (black line), and measured by flow cytometry. IgG2a antibody was used as isotype control (dotted line). (B) Dot plots of a 
selection of representative data from the same experiment. A coculture of the indicated reporter cells together with 721.221 cells containing HLA-C07:01 (221 Cw7, 
C1) or HLA-C06:02 (221-Cw6, C2) is shown. GFP expression was determined by flow cytometry. The E:T ratio was 1:3. (c) The data are depicted as the 
mean ± SD of individual samples collected from five independent experiments.
7
van der Ploeg et al. HCMV Affects KIR2DS1 Recognition
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 298
FigUre 3 | continued 
Kir2Ds1 reporter cells are not activated by interferon (iFn)-γ 
stimulated human fetal foreskin and primary dermal fibroblasts of 
healthy individuals. (a) Total human leukocyte antigen (HLA) class I (W6/32) 
and HLA-C/-E (DT9) expression levels of untreated and IFN-γ stimulated 
HFFFs (C2/C2) and DFs of donor CMV307 (C1/C1) and CMV0005 (C1/C2) 
were measured by flow cytometry. Gray = untreated, black = IFN-γ 
stimulated (500 U/ml, 72 h) and dotted line = isotype control. (B) The 
untreated and IFN-γ-stimulated fibroblasts were cocultured overnight with the 
indicated reporter cells, and green fluorescent protein (GFP) expression was 
measured by flow cytometry. Three independent experiments are depicted in 
the bar graphs as the mean ± SD of individual samples.
FigUre 3 | continued
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settings with IFN-γ stimulated cells. KIR2DL2 and KIR2DL1 
reporter cells were activated, in some conditions only minimally, 
depending on the particular HLA-C alleles expressed by the cells 
(Figure 3B). KIR2DS1 reporter cells were similarly unresponsive 
to tumor cell lines including HeLa, Meljuso, Caski, and JEG-3 
cells (data not shown). In conclusion, KIR2DS1 reporter cells 
were not activated after engaging with conventional C2-HLA-C 
molecules.
Kir2Ds1 reporter cells Bind a ligand on 
hFFFs infected with specific hcMV 
clones
Since KIR2DS1 reporter cells were not activated by conventional 
HLA molecules, we considered that KIR2DS1 might recognize a 
pathogen-induced ligand. Several studies have suggested a role 
for aKIR in HMCV infection (44–47). We therefore investigated 
whether the KIR2DS1 ligand might be upregulated after HCMV 
infection. HFFFs were infected with the HCMV TB40/E strain for 
24, 48, and 72 h and cocultured with the panel of reporter cells. 
HFFFs were used because they support full lytic HCMV infection 
(65) and express HLA-C02:02 and -C04:01, both C2-HLA-C.
HFFFs Infected with the TB40/E Wild-Type Strain 
Express a Ligand for KIR2DS1
In coculture, KIR2DS1 reporter cells increased in GFP positiv-
ity from 1% (uninfected and 24  h) to 5% (48  h) and to 21% 
positive cells (72  h) (Figure  4A). This indicates that KIR2DS1 
recognized a ligand, which was detected by the reporter cells 48 h 
p.i. with HCMV. In addition, there was increased triggering of 
both KIR2DL1 and LILRB1 reporter cells over time (Figure 4A). 
This was of interest as HCMV downregulates HLA class I mol-
ecules (66–71), and a decrease in KIR2DL1 reporter activation 
over infection time was expected. The increase in the LILRB1 
reporter cell activation might be explained by the recognition 
of UL18 protein, which HCMV produces as an immune evasion 
strategy (72, 73). Subsequently, in a total of 10 KIR2DS1 reporter 
cell coculture experiments with HFFFs infected with HCMV 
TB40/E strain were done, demonstrating the reproducibility of 
the KIR2DS1 reporter cell activation after infection (Figure S1 
in Supplementary Material). The KIR2DS1 ligand was only 
expressed on HFFFs infected with the TB40/E clinical strain and 
not with other strains tested, such as Merlin (another clinical 
strain) and AD169 (laboratory strain with deletion in the ULb’ 
region) (data not shown).
FigUre 4 | The Kir2Ds1 reporter cell recognizes a ligand on human fetal foreskin fibroblasts (hFFFs) infected with specific human cytomegalovirus 
(hcMV) strains. (a) Uninfected HFFFs and 24, 48, and 72 h infected HFFFs with HCMV TB40/E strain with an MOI of 10 were cocultured overnight with the 
reporter cells as indicated. A representative experiment of two independent time course cocultures is shown. (B) HFFFs were infected with six different 
TB40/E-isolated clones (E1, E4, F5, G1, D6, and F8) in 10-fold serial dilutions for 72 h and cocultured with KIR2DS1 reporter cells. A representative experiment from 
over three independent experiments is depicted. (c) The infectivities of three positive and three negative TB40/E clones were calculated by TCID50 assay and are 
depicted in the table (virus titers in PFU/ml). Viral particles were isolated from the supernatant, lysed, and loaded onto a 12% SDS-PAGE gel for western blotting 
with anti-pp28 antibody. Positive and negative clones were paired based on approximately the same infectivity. Equal amounts of lysate from these pairs were 
loaded onto the gel. (−) indicates a negative clone, (+) positive clone. (D) HFFFs were stimulated with UV-inactivated TB40/E, infected with the positive B6 or 
negative A8 clone for 72 h. Forty-eight hours p.i. KIR2DL2 (negative control), KIR2DL1, LILRB1 (positive control), and KIR2DS1 reporter cells were added. After an 
overnight coculture, the GFP expression was measured using flow cytometry. The data are depicted as the mean ± SD of individual samples collected from five 
independent experiments. *p < 0.05 and **p < 0.01 are calculated by non-parametric one-way ANOVA using the Kruskal–Wallis test and Dunn’s multiple 
comparisons test.
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Specific TB40/E Clones Activate the KIR2DS1 
Reporter Cells
Tomasec and colleagues isolated two viral clones, called Lisa and 
Bart, from the TB40/E strain, which had different functional 
properties (74). We wanted to investigate whether different viral 
clones were also present in our TB40/E strain. Multiple viral 
clones were isolated using a plaque purification assay. Twelve 
clones were selected and used to infect HFFFs followed by cocul-
ture with KIR2DS1 reporter cells. Six clones (B6, D7, E1, E4, E5, 
and F5) activated KIR2DS1 reporter cells (referred to as positive 
clones in what follows), while the other “negative” clones (A6, 
A8, D6, F2, F8, and G1) did not. Figure 4B depicts a representa-
tive coculture experiment where HFFFs were infected with six 
randomly selected clones in a 10-fold serial dilution for 72 h and 
then cocultured with KIR2DS1 reporter cells. The reporter cells 
were highly activated by HFFFs infected with the positive clones; 
E1, E4, and F5. They were not activated after infecting with nega-
tive clones; G1, D6, and F8 (Figure 4B). Infecting HFFFs with the 
positive clones resulted in a higher percentage of GFP-positive 
KIR2DS1 reporter cells (ranging from 16% by E4 clone to 50% 
by B6 clone) compared to the wild-type TB40/E strain (ranging 
from 4 to 21%, Figure S1 in Supplementary Material), indicat-
ing that the positive clones induced the KIR2DS1 ligand more 
efficiently. This is in line with the idea that the parental TB40/E 
strain contains a mixture of positive and negative viruses with 
respect to KIR2DS1 ligand expression.
Human cytomegalovirus infection indeed led to reduction 
in total HLA class I expression on most HFFFs as monitored by 
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binding of W6/32 antibody and this was true of both positive 
and negative clones (Figure 6A). This indirectly indicates that the 
positive and negative clones were equally infectious and consist-
ently infected over 90% of the HFFFs. In addition, the differential 
response of the KIR2DS1 reporter cells to the positive and negative 
clones was not due to differences in overall viral particle numbers 
of the different clones. This was demonstrated by comparing the 
infectivity (functional virus particles) with the total number of 
viral particles (functional and empty/non-functional particles) by 
detecting a structural tegument protein pp28 by western blot after 
pairing positive and negative virus clones based on approximately 
the same infectivity titer (Figure 4C).
KIR2DS1 Ligand Is Only Expressed on HFFFs after 
Infecting with Infectious Virus
Within the investigated infection timeframe, non-infected 
cells could be refractory for HCMV infection, yet exposed to 
pro-inflammatory cytokines, such as type I interferons (IFNs), 
which subsequently induce HLA class I surface expression. 
It was therefore critically important to investigate whether 
KIR2DS1 reporter cells were activated by the infected cells or 
by the surrounding non-infected cells. To examine this, TB40/E 
viruses were exposed to UV light for 30 min to inactivate the 
virus. After exposure, viral particles will be present and able 
to enter the cell, but the viral genes will be inactivated and 
will not be transcribed. Virus inactivation was confirmed by 
immunohistochemistry staining of Immediate Early 1 (I.E.1) 
viral proteins on the treated HFFFs, as shown in Figure S2 
in Supplementary Material. These UV-inactivated viruses are 
called “UV virus.”
After stimulating HFFFs with UV B6 clone and infecting with 
the positive B6 and negative A8 clones for 72 h, a coculture with 
parental, KIR2DL1, LILRB1, and KIR2DS1 reporter cells was 
performed. KIR2DS1 reporter cells were significantly activated 
in coculture with the active B6 clone-infected HFFFs, but not 
with UV B6-stimulated HFFFs nor in any other conditions, as 
shown in Figure  4D. By contrast, the KIR2DL1 reporter cells 
were highly activated after encountering UV B6-stimulated 
HFFFs, as well as with B6 clone-infected HFFFs (Figure  4D). 
Total HLA class I and HLA-C/-E cell-surface levels using W6/32 
and DT9 antibodies were assessed and both HLA-A, -B, -C and 
HLA-C/-E surface expression levels were highly increased on UV 
virus-stimulated HFFFs (Figure 6). Since fibroblasts are known 
to produce IFN-α and -β (75, 76), it was expected to see such an 
increase in HLA class I cell-surface levels, after exposure to viral 
particles. This is the host response to HCMV particles without 
the interference of HCMV genes downregulating HLA class I 
molecules.
In conclusion, from the different HCMV strains tested, 
only the TB40/E strain activated KIR2DS1 reporter cells after 
infecting HFFFs. Furthermore, the TB40/E strain consists of 
different virus clones and these virus clones differentially acti-
vated KIR2DS1 reporter cells. Since the clones have comparable 
amounts of functional viral particles, the levels of activation 
were not governed by the number of viral particles. We may also 
conclude that active viral gene expression is necessary to induce 
the KIR2DS1 ligand.
Primary, single-Positive Kir2Ds1 nK cells 
are Only activated in coculture when 
hFFFs are infected with specific hcMV 
clones
After establishing that KIR2DS1 reporter cells recognize a ligand 
on HFFFs infected with specific clones, we asked whether primary 
NK cells would also interact with these infected cells. Coculture 
experiments were performed using freshly isolated peripheral 
blood NK  cells from healthy individuals. NK  cells expressing 
KIR2DS1 are hyporesponsive, if the donor is homozygous for 
C2-HLA-C (32). We therefore chose donors that were C1-HLA-C 
homozygous, bearing fully functional KIR2DS1-positive NK cells. 
General NK cell functionality was verified using IL-12/15 primed 
NK  cells cocultured with the prototypic HLA class I negative 
NK cell target cell line K562 (positive control), or with no target 
cells (negative control). The KIR− NK cell subset represents the 
KIR-independent activation of NK cells, which is the background 
NK cell activation in this experiment.
Forty-nine percent of the cytokine-primed KIR− NK  cells 
degranulated after NK  cells of donor 016 encountered K562 
cells, and degranulation of 4% was observed in culture without 
target cells, indicating that the NK cells are functional, and little 
background activation was observed (Figure  5A). In the same 
experiment, rested NK  cells (without cytokine stimulation) 
were cocultured with HFFFs. NKG2A− cells were separated 
into KIR-negative (KIR−), KIR2DL1 single-positive (2DL1sp), 
and KIR2DS1 single-positive (2DS1sp) NK  cells. The gating 
strategy is described in Figure S3 in Supplementary Material. 
No response (1% CD107a expression) was seen from 2DS1sp 
NK cells cocultured with uninfected or UV B6 clone-stimulated 
HFFFs (Figure  5B). Similarly, minimal functional response 
from 2DS1sp NK cells was observed after coculture with HFFFs 
infected with the negative A8 clone (5% CD107a expression). 
Notably, 2DS1sp NK  cells engaging HFFFs infected with the 
positive B6 clone showed 20% CD107a expression (Figure 5B). 
Only a slight background activation of 3% was observed in the 
KIR− population in coculture with positive B6 clone-infected 
HFFFs. In all the other conditions, no degranulation in the 
KIR− population was observed. Furthermore, in every condition, 
including the positive B6 clone condition, no degranulation of 
2DL1sp NK cells was observed (Figure 5B). The experiment was 
repeated with isolated NK cells of donor 111, and these NK cells 
responded similarly, though slightly weaker, to the different types 
of treated HFFFs (Figure 5C). These results were reproducible 
in two independent coculture experiments using either isolated 
NK  cells (Figure S4A in Supplementary Material) or PBMCs 
(Figure S4B in Supplementary Material).
In conclusion, similar to the reporter cells, primary NK cells 
expressing KIR2DS1 recognize a ligand on HFFFs infected with 
specific clones of the TB40/E strain.
specific hcMV clones are less effective 
in Targeting hla-c
After confirming that the KIR2DS1 ligand is expressed on HFFFs 
infected with positive clones of HCMV, different HLA class I 
surface levels of uninfected HFFFs, UV B6 clone-stimulated 
FigUre 5 | Primary natural killer (nK) cells degranulated after coculture with human fetal foreskin fibroblasts (hFFFs) infected with the positive B6 
TB40/e clone. (a) After NK cell isolation, the NK cells of donor 016 were rested or stimulated with IL-12 and IL-15 overnight. IL12/IL15-stimulated NK cells were 
cocultured with and without K562 cells. (B) Unstimulated NK cells were cocultured with uninfected HFFFs, UV B6 clone-stimulated HFFFs (UV), negative A8 clone- 
(A8 neg), and positive B6 clone-infected HFFFs (B6 pos). After harvesting, the NK cells were stained with antibodies targeting different surface markers and the 
degranulation marker CD107a. NK cells from the KIR-negative (KIR), KIR2DL1 single-positive (2DL1sp), and KIR2DS1 single-positive (2DS1sp) subsets are shown. 
The percentage of CD107a expression is depicted. The NK subsets are grouped on NKG2A− NK cells (A−). (c) The same coculture experiment with NK cells of 
donor 016 is represented in a bar graph (left) including coculture data of NK cells of donor 111 (right). The percentage of CD107a expression is shown. All 
cocultures were performed for 5 h at an E:T ratio of 1:1. A representative data from three independent coculture experiments are shown. The other two independent 
experiments are illustrated in Figure S4 in Supplementary Material.
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HFFFs, and both positive and negative clone-infected HFFFs 
were compared. Surface expression of HLA-E (3D12), HLA-C/-E 
(DT9), total HLA class I (W6/32), HLA-A11, HLA-Bw6, total free 
heavy chain (FHC) of HLA class I (HC10), and FHC of HLA-C 
(L31) was analyzed. The antibodies used are listed in Table  1 
with a description of their specific recognition patterns and are 
discussed below.
Free Heavy Chain of HLA-C and Assembled HLA-C 
Remain on the Cell Surface of HFFFs Infected with 
Positive Clones
Positive and negative clones both reduced total HLA class I, 
HLA-E, HLA-Bw6, and HLA-A11 cell-surface levels on infected 
HFFFs compared to the UV B6 clone-stimulated HFFFs (p < 0.05 
and p < 0.01, Figures 6A,B). However, using antibodies to FHC 
forms of HLA, such as HC10 and, in particular, L31 staining was 
higher in HFFFs infected with the positive clones compared to 
the negative clones. FHC HLA-C levels, as detected by L31, were 
close to the levels of UV B6-stimulated HFFFs, indicating that 
the positive clones did not effectively downregulate the FHC 
HLA-C surface levels (Figures 6A,B). This difference observed 
in L31 staining was reproducible in every experiment performed 
(n = 11) and in an experiment where FHC HLA-C surface levels 
were compared in HFFFs infected with 12 additionally isolated 
clones comprising six positive and six negative clones (Figure S5A 
in Supplementary Material). Similar differences between the 
clones were observed with HC10 staining (FHC of HLA class 
I molecules, Figures 6A,B). This difference could be due to the 
antibody detecting the elevated FHC of HLA-C specifically. 
However, this remains uncertain, because specific antibodies 
against FHC of HLA-A and -B are not available.
The DT9 staining (detects conformational HLA-C/-E con-
taining β2M) was slightly weaker and less consistent than L31, 
but similar differences between the clones were measurable 
(Figures  6A,B). Since DT9 antibody cross-reacts with HLA-E 
(56), an anti-HLA-E monoclonal antibody (3D12) was included. 
HLA-E surface expression in general was very low on HFFFs 
(Figure  6A) and no difference was observed between HFFFs 
infected with positive and negative HCMV clones (Figure 6B). 
Low HLA-E expression in the infected HFFFs is most likely due 
to a mutation at position 2 (Met to Val) in the canonical sequence 
(VMAPRTLIL) of UL40 expressed in all the TB40/E clones, as 
described previously (77). This result implies that the difference 
observed in the DT9 staining is, most likely, due to higher HLA-C 
expression and not HLA-E expression. In addition, assembled 
HLA-C and FHC of HLA-C surface levels on HFFFs infected with 
other viral strains, such as Merlin and AD169, were downregu-
lated comparable to the surface levels found with the negative 
clones (Figure S6 in Supplementary Material). Together, these 
results indicate that the positive clones are less effective in down-
regulating assembled HLA-C and, in particular, FHC of HLA-C 
in HFFFs, compared to the negative clones and other HCMV 
strains. However, both sets of clones downregulated other HLA 
molecules to similar levels.
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FigUre 6 | continued
FigUre 6 | continued 
human leukocyte antigen (hla) class i surface and total hla-c protein expression of infected human fetal foreskin fibroblasts (hFFFs). (a) Dot plots 
(left) and histograms (right) from the same representative experiment are shown. The HFFFs infected with the indicated positive or negative clones and the UV B6 
clone-stimulated HFFFs (UV) were treated for 72 h. The indicated treated HFFFs were stained subsequently with W6/32 (total HLA class I), DT9 (HLA-C/-E), 3D12 
(HLA-E), L31 (FHC HLA-C), and HC10 (FHC HLA class I) antibodies (black line). Cells stained with the appropriate isotype control (dotted line) were included. (B) 
Collection of up to four independent cell-surface staining experiments is depicted in bar graphs as the mean ± SD of individual samples. Anti-Bw6 and anti-A11 
antibodies were also included. The percentage change in MFI is depicted with the uninfected condition at 100%. *p < 0.05 and **p < 0.01 are calculated by 
non-parametric one-way ANOVA using the Kruskal–Wallis test and Dunn’s multiple comparisons test. (c) Total lysate of uninfected, UV B6 clone-stimulated (UV), 
positive clones- (E5, D7, B6), and negative clones (F2, F8, A6)-infected HFFFs were loaded onto a reduced 10% SDS-PAGE gel. The membrane was blotted with 
the L31, anti-I.E.1 viral protein (measure of infection) and anti-calnexin (loading control) antibodies.
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More Total HLA-C Protein Is Expressed on HFFFs 
Infected with Selected Clones of HCMV
After having found that HLA-C and, in particular, FHC of HLA-C 
cell-surface levels were higher on positive clone-infected HFFFs, 
we investigated whether differential expression of total HLA-C 
protein levels could be tracked by western blot. HFFFs infected 
with three positive clones had higher amounts of total HLA-C 
compared to the negative clones, although the levels in general 
were lower than for the uninfected and UV B6 clone samples. As 
expected, HFFFs stimulated with UV B6 clone contained high 
amounts of HLA-C protein (Figure 6C). Additionally, we tested 
HFFFs infected with a further 12 clones (6 positive and 6 nega-
tive, Figure S5B in Supplementary Material). From the 18 clones 
tested in total, 7 positive clones had high amounts of total HLA-C, 
while 7 negative clones had lower amounts.
In conclusion, positive TB40/E clones are defective in down-
regulating HLA-C and, in particular, FHC of HLA-C in HFFF cells. 
Higher amounts of total HLA-C protein were found in HFFFs 
infected with the positive TB40/E clone compared to infection 
with the negative TB40/E clone. This may reflect a deficiency in 
degradation/turnover of HLA-C by positive TB40/E clones.
Pan hla class i antibodies Block the 
Kir2Ds1–ligand interaction
Antibody-blocking experiments were performed using various 
anti-HLA class I antibodies to obtain a better understanding 
of the KIR2DS1 interaction. Previously, Stewart and colleagues 
tested a large panel of pan HLA class I antibodies in a blocking 
experiment to analyze the interaction of KIR2DL1 and KIR2DS1 
tetramers with 221-HLA-C transfectants (27). They concluded 
that W6/32 and HC10 antibodies were not able to block both 
KIR2DL1 and KIR2DS1 tetramer interactions with C2-HLA-C. 
However, other pan HLA class I antibodies, such as 6A4 and 
B1.23.2, did block (27). To confirm the previous findings, the 
interaction of KIR2DL1 reporter cells with UV B6-stimulated 
HFFFs, which highly expressed all HLA class I molecules, was 
tested. As expected, W6/32 antibody did not block the KIR2DL1 
interaction with the HFFFs, but the 6A4 and B1.23.2 antibodies 
did (Figures 7A,B, left panels). Next, the HFFFs were infected 
with the positive B6 clone and the antibody blocking experiment 
was repeated. W6/32, 6A4, and B1.23.2 antibodies blocked the 
KIR2DS1 reporter cell interaction with B6 clone-infected HFFFs. 
Notably, the W6/32 antibody did not block and the 6A4 and 
B1.23.2 antibodies only partially blocked the KIR2DL1 reporter 
cell interaction (Figures  7A,B, right panels). Furthermore, 
DT9, L31, and HC10 antibodies were also not able to block the 
KIR2DS1–ligand interaction and the anti-β2M only partially 
(data not shown). Together, these data are consistent with a 
differential mode of recognition of C2-HLA-C by KIR2DL1 and 
KIR2DS1.
hFFFs with a β2M KO infected with 
Positive hcMV clones Do not induce the 
Kir2Ds1 ligand
To confirm whether the KIR2DS1 ligand is a HLA class I mol-
ecule and specifically HLA-C, the β2M gene was knocked out of 
HFFFs. The HLA class I complex cannot be formed without β2M 
and therefore, HLA class I molecules, but also FHC of HLA class 
I, will not be transported efficiently to the cell surface (78). The 
β2M gene was knocked out by using the CRISPR/CAS9 genome 
editing tool (79). After selection and single-cell sorting, β2M KO 
HFFFs were checked for β2M, total HLA class I (W6/32), and 
FHC of HLA-C (L31) surface expression by flow cytometry and 
total protein expression by western blot. β2M KO HFFFs did 
not express surface β2M, total HLA class I, and FHC of HLA-C. 
B6 and A8 clone infection did not alter these expression levels 
(Figure 8A). Total β2M, total HLA class I (detected with HC10), 
and most HLA-C protein were also absent in the β2M KO HFFFs, 
compared to the untreated HFFFs (WT) and HFFFs containing 
CAS9 without the sgRNA (CAS9), indicating that the β2M KO 
was successful (Figure 8B).
Subsequently, β2M KO HFFFs and WT HFFFs, either stimu-
lated with UV B6 clone or infected with a positive and negative 
clone, were cocultured with the KIR2DS1, -L1, -L2, and LILRB1 
reporter cells. The KIR2DS1 reporter cell was not activated after 
encountering β2M KO HFFFs infected with the positive B6 clone, 
while, in the same experiment, 44% of KIR2DS1 reporter cells 
were GFP positive after coculture with B6 clone-infected WT 
HFFFs (Figure  8C). KIR2DL1 and LILRB1 reporter cells were 
not significantly triggered by β2M KO HFFFs in all the conditions 
(Figure 8C).
This result is consistent with KIR2DS1 recognizing an HLA 
class I molecule, including HLA-C. Together with the cell-surface 
staining and the antibody-blocking experiment, the data suggest 
that modulation of C2-HLA-C by HCMV induces a potent 
KIR2DS1-mediated NK cell activation.
FigUre 7 | antibody-blocking experiment of reporter cells and hFFFs stimulated with UV B6 clone or infected with the B6 clone. W6/32, 6A4, 
B1.23.2, and isotype antibodies were added to 72 h UV-stimulated or infected HFFFs, before an overnight coculture with KIR2DS1 and KIR2DL1 reporter cells was 
performed. GFP expression was measured by flow cytometry. (a) The dot plots are data from a representative experiment. (B) Collection of up to five independent 
blocking experiments is depicted in bar graphs as the mean ± SD of individual samples with *p < 0.05 calculated by non-parametric one-way ANOVA using the 
Kruskal–Wallis test and Dunn’s multiple comparisons test.
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DiscUssiOn
We found that KIR2DS1 recognizes a ligand on HFFFs infected 
with the TB40/E strain of HCMV. This wild type strain consists of 
at least two sets of virus clones: one set that, after HFFF infection, 
activates KIR2DS1-expressing cells (positive clones) and one 
that does not (negative clones). This specific KIR2DS1 recogni-
tion was only present when the HFFFs were infected with fully 
functioning viruses, indicating that the virus plays a direct role 
in expressing the KIR2DS1 ligand. In addition, KIR2DS1 single-
positive (2DS1sp) primary NK cells degranulated after engaging 
with positive clone-infected HFFFs. Together, this indicates that 
KIR2DS1 reporter cell activation correlates with physiological 
KIR2DS1 binding to its ligand.
The reporter system is a Valid Way of 
examining Kir specificity
Using the reporter system, we confirmed that a single amino 
acid substitution K70T in KIR2DS1 altered the recognition from 
no binding to binding the same cognate ligands as KIR2DL1 
(Figure 1C). This confirms the important role of residue 70 in 
the binding avidity to HLA-C by KIR2DL1/2DS1. These findings 
together with the differential recognition of HLA-C alleles by 
LILRB1, KIR2DL1, and -2DL2 reporter cells (Figure 2C) indicate 
that the reporter system is sensitive to subtle differences. One pos-
sible explanation of KIR2DL1 and -L2 reporter cells responding 
minimally to DFs (Figure 3B) is that there is binding of KIR to its 
ligand, but this binding is not strong enough to trigger a signal-
ing cascade to activate the reporter cell. The signaling cascade 
FigUre 8 | β2M KO hFFFs do not activate Kir2Ds1 reporter cells. (a) To control the success of the β2M knockout, untreated (WT) HFFFs (black line) and β2M 
KO HFFFs (shaded gray line) were stained with anti-β2M, W6/32, and L31 antibodies. Before staining, the cells were stimulated with UV clone (UV) or infected for 
72 h with the positive B6 clone (B6 pos) or the negative A8 clone (A8 neg). Unstained cells were included (dotted line). (B) Total lysate of β2M KO HFFFs, HFFFs 
containing CAS9 without sgRNA (CAS9) and WT HFFFs were loaded onto a reduced 10% SDS-PAGE gel. The membrane was blotted with the anti-β2M, L31, 
HC10, anti-M2 Flag, and anti-calnexin (loading control) antibodies. (c) β2M KO HFFFs and WT HFFFs were stimulated with UV B6 clone (UV) and infected with the 
positive B6 clone (B6 pos) or negative A8 clone (A8 neg) for 72 h. An overnight coculture was performed with KIR2DL2 (negative control), KIR2DL1, KIR2DS1, and 
LILRB1 reporter cells. GFP expression was measured by flow cytometry. This experiment was performed twice.
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will only be triggered if there is a true interaction. The degree 
of receptor/ligand clustering might also influence the down-
stream signaling, as shown by Oszmiana et  al. (80). Therefore, 
the reporter cells may be a more physiological system compared 
to Fc proteins or tetramers.
Kir2Ds1 interacts with hla-c but not in 
the same Way as Kir2Dl1
There are several examples of “paired” immunoreceptors consist-
ing of almost identical external moieties with positive and negative 
signaling tails, respectively (13). It is believed, but by no means 
proven, that this situation is driven by host–pathogen interac-
tion. Our data are broadly consistent with this proposal. Our 
data fit with KIR2DL1, the inhibitory receptor, interacting with 
C2-HLA-C for recognition of a self-ligand in order to promote 
education/licensing of NK cells and subsequent loss of inhibition 
when the ligand is missing. By contrast, the role of aKIR has 
been unclear. Some groups reported weak binding, particularly 
for KIR2DS1, but these effects are inconsistent. In general, aKIR 
appear to interact with HLA molecules weakly except in certain 
circumstances (27, 41, 42). We found that KIR2DS1 reporter 
cells were not activated after engaging conventional HLA class 
I molecules (Figures  2 and 3), as shown previously by others 
(10, 11, 17, 24–35). There is a possibility that the target cells used 
in previous KIR2DS1 studies did not only express conventional 
HLA-C molecules. These cells were EBV positive (721.221 cells, 
BLCLs, C1R cells), and/or tumor-derived cells, such as leuke-
mia blasts and lymphomas. In addition, other studies included 
primary cells such as DCs (33), T cells (30, 33), B cells (27, 29), 
and MRC-5 fibroblasts (supplementary data of Stewart et  al.) 
KIR2DS1 did not interact with or bind these primary cells, unless 
they were stimulated: in the case of DCs, stimulated with LPS and 
T cells, stimulated with PHA to form T cell blasts. Furthermore, 
Crespo et  al. found that HCMV-infected JEG-3 cells and fetal 
extravillous trophoblasts (EVT) did not induce degranulation 
and cytokine production of dNK cells. They only found a cyto-
toxic response when dNK cells were exposed to HCMV-infected 
DSC specifically, indicating differential recognition of dNK cells 
FigUre 9 | summary of the findings and working models. (a) Both 
KIR2DL1 (red) and -2DS1 (green) bind conventional group C2 human 
leukocyte antigen (HLA)-C; however, KIR2DS1 binds weakly. Our data were 
consistent with previous studies demonstrating that the W6/32 antibody 
does not block the KIR2DL1–HLA-C interaction. The lightning bolt indicates 
KIR2DL1 triggering even after adding W6/32 to the coculture. (B) Strong 
KIR2DS1 activation was observed after coculture with HFFFs-infected 
selected TB40/E clones. After infecting β2M KO HFFFs with selected TB40/E 
clones, KIR2DS1 interaction was diminished (left). In addition, W6/32 blocked 
the KIR2DS1–ligand interaction after coculture with HFFFs-infected selected 
TB40/E clones (right). *Other pan class I antibodies, such as 6A4 and 
B1.23.2, blocked both KIR2DL1 and KIR2DS1 interaction. The red symbol 
indicates no binding of KIR2DS1 after coculture in the indicated setting. (c) 
Remaining FHC of HLA-C and, to certain extent, assembled HLA-C surface 
expression was found on infected HFFFs. Together with the other findings, 
we hypothesize that a modification of C2-HLA-C is induced by HCMV, which 
influences KIR2DS1 recognition. This modification could relate to the 
following: presentation of HCMV-derived peptides; alteration of glycosylation 
patterns on the HLA-C molecule; formation of HLA-C homodimers; or 
heterodimers association with another protein.
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to HCMV-infected cells (47). One explanation could be that 
KIR2DS1-mediated NK cell activation could only occur through 
an unknown synergistic engagement of other activating recep-
tors, as proposed by Bryceson et al. (81). Additionally, perhaps 
a high level of C2-HLA-C is needed for a potent KIR2DS1-
mediated NK cell activation, which is the case for these target 
cells. Primary cells might express too low levels of C2-HLA-C and 
in combination with the weak binding of KIR2DS1 to C2-HLA-C 
might result in the absence of NK cell activation. Crespo et al. 
also found reduced levels of HLA-C on HCMV-infected DSC 
leading the authors to speculate that an unknown activating 
ligand for KIR2DS1 is upregulated by HCMV infection which is 
recognized by dNK cells (47). Alternatively, our findings indicate 
that KIR2DS1 might recognize a modified form of C2-HLA-C, 
which is induced by selected TB40/E clones in HFFFs. Compared 
to HCMV from other sources, positive TB40/E clones were 
less effective in controlling FHC of HLA-C and, to a certain 
extent, assembled HLA-C (Figure 6). W6/32, 6A4, and B1.23.2 
antibodies were able to block the KIR2DS1–ligand interaction 
on positive clone-infected HFFFs, while these antibodies could 
not block, or only partially block, the KIR2DL1 interaction 
(Figure 7). β2M KO experiments confirmed that KIR2DS1 binds 
a HLA class I molecule, most likely HLA-C, on these infected 
cells (Figure 8). It is unlikely that KIR2DS1 was binding directly 
to an HCMV-encoded protein, since KIR2DS1 reporter cells 
were not activated in coculture with β2M KO HFFFs infected 
with the positive clone. The most parsimonious interpretation 
is that the virus influences the balance of recognition directly of 
HLA-C by the KIR2DL1/S1 pair. At this stage, however, other 
possibilities cannot be ruled out, such as a combination of HLA 
class I with another protein.
What is the Difference Between hla-c 
recognized by Kir2Ds1 and by Kir2Dl1?
Since all the data indicate that HLA-C forms at least part of the 
KIR2DS1 ligand the question that arises is how does HLA-C dif-
fer upon viral infection such that KIR2DS1 is brought into play? 
Figure 9 suggests various models which may be tested, namely:
 1. Bound peptide: there have been reports of KIRs recognizing 
certain peptide motifs presented by HLA class I molecules. 
Stewart and colleagues have demonstrated that amino acids 
at position 7 and 8 of the peptide play a role in KIR2DS1 
binding. KIR2DS1 has similar peptide selectivity to KIR2DL1 
(27). Work from Khakoo’s group has shown that peptides with 
certain motifs have either strong inhibitory, low inhibitory, or 
antagonistic effects on KIR2DL2 and -2DL3+ NK cells (82). 
These data suggest that NK cells are able to sense alterations 
of target cells, through selective peptide recognition.
 2. Modified glycosylation: KIR3DL1 binding to HLA-B57:01 
is dependent on the N-glycan on HLA-B57:01. Removing 
the N-glycan resulted in reduced inhibition, thus increas-
ing degranulation of KIR3DL1+ NK  cell clones (38). The 
N-glycosylation site on HLA class I is highly conserved 
and the glycan structures on HLA-C are relatively uniform 
between HLA-C allotypes (83). Perhaps viral infections could 
alter these glycosylation patterns and break the uniformity, 
resulting in the recognition of KIR2DS1. HIV and HCV infec-
tion has been shown to alter glycosylation in host cells, due to 
ER stress (84, 85). This might change the glycosylation pattern 
of HLA class I.
 3. Formation of HLA-C homodimers or heterodimers with other 
HLA class I molecules: KIR3DL2 binds FHC forms of HLA-
B27, including HLA-B27 dimers (86). LILRB1 interacts with 
different HLA class I molecules, which are able to dimerize 
via a cysteine residue in the cytoplasmic tail (49). Recently, 
it is described that the ligand for KIR3DS1 is FHC of HLA-F 
(41, 42). These data are evidence of the capability of Ig-like 
receptors to bind FHC HLA molecules or HLA homodimers.
 4. Modification by formation of HLA-C heterodimers with a 
virus-derived protein: in mice, activating receptor Ly49P bind-
ing to an MHC-CMV protein heterodimer has been reported. 
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Ly49P binds CMV-infected cells expressing a complex of the 
m04 CMV protein together with the MHC class I molecule 
H-2Dk (87). Very recently, Serena et al. proposed that HIV-1 
Env protein associates with FHC of HLA-C and that HIV-1 
specifically upregulates FHC of HLA-C at the cell surface of 
infected cells (88). Their work has some parallels with our 
findings. Our preliminary experiments, however, did not 
show any evidence of HLA-C forming homo- or heterodimers 
(data not shown).
Based on these observations together with our findings, we 
argue that KIR2DS1 most likely binds C2-HLA-C either through 
recognizing HCMV-derived peptide or changes in glycosylation 
patterns. This will be the focus of future experiments.
have activating Kirs evolved to 
recognize infected cells?
Studies investigating the evolution of KIRs and other paired 
receptors have proposed that the activating members may be 
evolving more rapidly than the inhibitory members through 
selection imposed by pathogens (15, 16). The positively charged 
lysine at position 70 in KIR2DS1 is critical for the diminished 
binding to C2-HLA-C compared to KIR2DL1. This amino acid 
is conserved in all KIR2DS1 allotypes (with the exception of 
KIR2DS1*001, which has a charged arginine) (11). Conversely, 
the lysine at position 70 in KIR2DS1 could be crucial for bind-
ing modified HLA-C induced by pathogens. KIR2DL1 might 
have evolved to recognize HLA-C on healthy cells (induced-
self), while KIR2DS1 might recognize slight structural changes 
on HLA-C induced by pathogens (altered-self). KIR2DS1 may 
still bind conventional HLA-C weakly to secure tolerance, yet 
recognition by KIR2DS1 of a modified form of HLA-C could 
overcome this tolerance. Our findings favor this hypothesis.
Why Were Kir2Dl1 reporter cells More 
activated after encountering 
TB40/e-infected hFFFs?
The GFP expression of KIR2DL1 reporter cells, after encounter-
ing TB40/E-infected HFFFs, was even higher than in coculture 
with UV TB40/E-stimulated HFFFs, which contain high expres-
sion levels of HLA-C (Figure 4A). HCMV downregulates HLA 
class I molecules, thus these findings were unexpected. A possible 
explanation is that KIR2DL1 binds the remaining HLA-C on the 
infected cell surface (Figure  6B). Ameres et  al. reported that 
HCMV downregulates certain HLA-A and -B alleles more effi-
ciently than HLA-C alleles (89, 90). Another explanation could 
be that KIR2DL1 recognizes an alternative ligand, comparable to 
how both inhibitory Ly49I and activating Ly49H-binding m157 
(43, 91).
Differences in hcMV isolates
Natural killer cell responses appear to differ when encountering 
cells infected with various HCMV strains and even clones within 
strains. Chen et al. also demonstrated that the ability of NK cells 
to control virus spread through LILRB1 was variable between 
HCMV viral strains, depending on the amino acid sequence 
within UL18 (92). Thus, the variable effect between HCMV 
strains on NK cell activity and vice versa should be taken into 
account when setting up experiments and interpreting published 
data. This will also count for cytotoxic T cells and other immune 
cell responses.
TB40/E-derived positive clones were the only viruses that, 
upon infecting HFFFs, expressed the KIR2DS1 ligand. Together, 
these findings imply that after infection the positive clones are less 
successful in downregulating the KIR2DS1 ligand than TB40/E-
derived negative clones or other HCMV strains. As a result, 
KIR2DS1 reporter cells and 2DS1sp NK  cells are specifically 
detecting the ligand on positive clone-infected HFFFs. This sug-
gests that the other HCMV strains are capable of downregulating 
the KIR2DS1 ligand as an immune evasion strategy to NK cells. 
Our findings could explain why this interaction has not been 
detected in previous studies. Identification of the differences 
between the positive and negative clones by whole virus genome 
sequencing should help to resolve this issue.
cOnclUsiOn
Our findings indicate that activating KIRs do not bind the same 
conventional HLA molecules as their inhibitory counterparts. 
They suggest that pathogenic infections are required for strong 
activating KIR binding, discriminating between healthy and 
unhealthy cells. To our knowledge, this is the first time that the 
role of HCMV on activating KIR recognition has been conclu-
sively shown. Future work will provide new insights into the role 
of NK cells in HCMV infection and transplantation. This could 
lead to more targeted and effective therapeutic avenues in the 
treatments for HCMV infection in new-born babies, immuno-
suppressed individuals, and patients undergoing solid organ or 
HSCT transplantation.
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